Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STALWART: Aldesleukin with and without antiretroviral therapy in HIV infection
2005-001490-95Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2005
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aldesleukin in human immunodeficiency virus infection (HIV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Mean change in CD4+ T-lymphocyte count from baseline to 32 weeks. Started Nov 2005; status: completed.
02
Drugs
aldesleukin
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2005-001490-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001490-95.